171 related articles for article (PubMed ID: 11474786)
21. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
[TBL] [Abstract][Full Text] [Related]
22. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Kobayashi K; Bouscarel B; Matsuzaki Y; Ceryak S; Kudoh S; Fromm H
Int J Cancer; 1999 Nov; 83(4):491-6. PubMed ID: 10508485
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous determination of the lactone and carboxylate forms of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in rat plasma by high performance liquid chromatography.
Kaneda N; Hosokawa Y; Yokokura T
Biol Pharm Bull; 1997 Jul; 20(7):815-9. PubMed ID: 9255427
[TBL] [Abstract][Full Text] [Related]
24. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.
Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
Cancer Chemother Pharmacol; 2000; 46(3):211-20. PubMed ID: 11021738
[TBL] [Abstract][Full Text] [Related]
25. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Morton CL; Iacono L; Hyatt JL; Taylor KR; Cheshire PJ; Houghton PJ; Danks MK; Stewart CF; Potter PM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):629-36. PubMed ID: 15918039
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
[TBL] [Abstract][Full Text] [Related]
27. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Res; 1996 Aug; 56(16):3752-7. PubMed ID: 8706020
[TBL] [Abstract][Full Text] [Related]
28. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma.
Rivory LP; Robert J
J Chromatogr B Biomed Appl; 1994 Nov; 661(1):133-41. PubMed ID: 7866541
[TBL] [Abstract][Full Text] [Related]
29. Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
Yokooji T; Kawabe Y; Mori N; Murakami T
J Pharm Pharmacol; 2013 Feb; 65(2):280-91. PubMed ID: 23278696
[TBL] [Abstract][Full Text] [Related]
30. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.
Sadzuka Y; Hirotsu S; Hirota S
Jpn J Cancer Res; 1999 Feb; 90(2):226-32. PubMed ID: 10189894
[TBL] [Abstract][Full Text] [Related]
31. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.
de Bruijn P; Verweij J; Loos WJ; Nooter K; Stoter G; Sparreboom A
J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):277-85. PubMed ID: 9367218
[TBL] [Abstract][Full Text] [Related]
32. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
Takasuna K; Kasai Y; Kitano Y; Mori K; Kobayashi R; Hagiwara T; Kakihata K; Hirohashi M; Nomura M; Nagai E
Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
[TBL] [Abstract][Full Text] [Related]
33. Characterization of secretory intestinal transport of the lactone form of CPT-11.
Takemoto I; Itagaki S; Chiba M; Itoh T; Hirano T; Iseki K
Cancer Chemother Pharmacol; 2006 Jan; 57(1):129-33. PubMed ID: 16003561
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats.
Atsumi R; Okazaki O; Hakusui H
Biol Pharm Bull; 1995 Aug; 18(8):1114-9. PubMed ID: 8535406
[TBL] [Abstract][Full Text] [Related]
35. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
Onoue M; Kurita A; Kado S; Matsumoto T; Kaneda N; Uchida K; Kato I; Yokokura T
Cancer Chemother Pharmacol; 2008 Apr; 61(4):595-605. PubMed ID: 17549477
[TBL] [Abstract][Full Text] [Related]
36. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
[TBL] [Abstract][Full Text] [Related]
37. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.
Zastre J; Anantha M; Ramsay E; Bally M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):91-102. PubMed ID: 17009029
[TBL] [Abstract][Full Text] [Related]
38. Novel agents that potentially inhibit irinotecan-induced diarrhea.
Yang X; Hu Z; Chan SY; Chan E; Goh BC; Duan W; Zhou S
Curr Med Chem; 2005; 12(11):1343-58. PubMed ID: 15975002
[TBL] [Abstract][Full Text] [Related]
39. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
[TBL] [Abstract][Full Text] [Related]
40. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats.
Scott DO; Bindra DS; Sutton SC; Stella VJ
Drug Metab Dispos; 1994; 22(3):438-42. PubMed ID: 8070321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
